Brain natriuretic peptide (BNP) and N-terminal prohormone of BNP (NT-proBNP) serve as crucial biomarkers in pulmonary arterial hypertension (PAH). Nevertheless, test results are seldom accessible during clinical evaluations. A study published on Respirology on July 3, 2025, examined the reliability of NT-proBNP/BNP point-of-care tests (POCT) in pulmonary arterial hypertension patients and assessed the stability of NT-proBNP in mailed blood samples to evaluate remote monitoring feasibility.
The authors conclude that the data support the use of point-of-care tests NT-proBNP as a rapidly accessible and reliable alternative in clinical settings and highlight the potential of NT-proBNP for remote monitoring via posted samples.
Read more at this link on Respirology
Citation
Durrington C, Battersby C, Holt L, Fairman A, Strickland S, Salisbury T, Turton HA, Watson L, Smith I, Roman S, Ablott J, Hitchcock F, Roddis C, Oakes E, Wilshaw H, Woodrow I, Armstrong I, Charalampopoulos A, Elliot CA, Hameed A, Hamilton N, Hurdman JA, Lawrie A, Middleton JT, Zafar H, Rothman AMK, Condliffe R, Lewis RA, Kiely DG, Thompson AAR. NT-proBNP and BNP Testing in Pulmonary Arterial Hypertension: Point-of-Care and Remote Monitoring. Respirology. 2025 Jul 3. doi: 10.1111/resp.70087. Epub ahead of print. PMID: 40611611.
